KCNH2 and cancer: The majority of drugs cause QTc interval prolongation by inhibition of the hERG subunit of the channel that conducts major ventricular repolarizing potassium current (IKr) during phases 2–3 of the action potential.45,46 In TKI-initiated cancer patients with concomitant CV drug intake, regular ECG monitoring is strongly recommended.